Active Biotech AB (FRA:BTP) Total Stockholders Equity: €3.39 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:BTP Active Biotech AB FRA:BTP
30 GF Score
Price €0.41
GF Value €0.13
Valuation Significantly Overvalued
! 1 Warning Sign
View Full Analysis

What is Active Biotech AB Total Stockholders Equity?

Active Biotech AB FRA:BTP +0.86% 30 Total Stockholders Equity is €3.39 Mil as of Jun. 2026. GuruFocus rates FRA:BTP with a GF Score™ of 30/100 and a GF Value™ of €0.13 (Significantly Overvalued). The stock has 1 warning sign investors should review.

Active Biotech AB's Total Stockholders Equity for the quarter that ended in Jun. 2026 was €3.39 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Active Biotech AB's Book Value per Share for the quarter that ended in Jun. 2026 was €0.13. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Active Biotech AB's Debt-to-Equity for the quarter that ended in Jun. 2026 was 0.00.

Active Biotech AB  (FRA:BTP) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Active Biotech AB's Book Value per Share for the quarter that ended in Jun. 2026 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(3.393-0)/26.361
=0.13

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Active Biotech AB's Debt-to-Equity for the quarter that ended in Jun. 2026 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0 + 0) / 3.393
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Active Biotech AB Total Stockholders Equity Related Terms

Active Biotech AB Total Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Active Biotech AB's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Active Biotech AB Total Stockholders Equity Chart

Active Biotech AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.54 3.14 2.74 2.85 5.11

Active Biotech AB Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.95 0.41 5.11 4.38 3.39
FRA:BTP
30GF Score
Active Biotech AB FRA:BTP
Total Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Total Stockholders Equity of €3.39 Mil mean?
Active Biotech AB (FRA:BTP) has a Total Stockholders Equity of €3.39 Mil as of Jun. 2026. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Active Biotech AB and its competitors.
Is Active Biotech AB's Total Stockholders Equity too high?
Active Biotech AB's current Total Stockholders Equity is €3.39 Mil. Overall, Active Biotech AB has a GF Score™ of 30/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Active Biotech AB's Total Stockholders Equity compare to VRTX and REGN?
Active Biotech AB's Total Stockholders Equity of €3.39 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Stockholders Equity for a Biotechnology company?
A good Total Stockholders Equity depends on the Biotechnology industry context. However, Total Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Stockholders Equity mean?
A high Total Stockholders Equity can signal that a stock is expensive relative to its fundamentals. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Active Biotech AB and its competitors. Active Biotech AB's current Total Stockholders Equity is €3.39 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Active Biotech AB stock overvalued right now?
Based on GuruFocus' analysis, Active Biotech AB (FRA:BTP) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.13, compared to a current price of €0.41 — trading 214.2% above its estimated fair value. The current Total Stockholders Equity is €3.39 Mil. Active Biotech AB's overall GF Score™ is 30/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Stockholders Equity calculated?
Total Stockholders Equity is calculated from a company's financial statements. For Active Biotech AB (FRA:BTP), the current Total Stockholders Equity is €3.39 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Active Biotech AB (FRA:BTP) Overvalued in 2026?

Based on GuruFocus' analysis, Active Biotech AB stock appears to be overvalued. The current stock price of €0.41 is trading 214.2% above its estimated GF Value™ of €0.13. GuruFocus considers Active Biotech AB to be Significantly Overvalued.

Key valuation signals for FRA:BTP:

  • Total Stockholders Equity: €3.39 Mil
  • GF Value™: €0.13 vs. price of €0.41 (214.2% above fair value)
  • GF Score™: 30/100 with 1 warning sign

No single metric tells the full story. See the FRA:BTP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Active Biotech AB Business Description

Other Exchanges ACTI:Sweden0GQU:UK
Address Scheelevagen 22, P.O. Box 724, Lund, SWE, 223 63
Active Biotech AB focuses on the research and development of pharmaceuticals products within medical areas including neurodegenerative diseases, autoimmune/inflammatory disease and various forms of cancer. Its project portfolio contains both small molecules that are orally active immunomodulatory agents and antibody based immunotherapy. Its project portfolio includes both small orally active immunomodulatory molecules and antibody-based immunotherapy. Its pipeline products are: Tasquinimod, Laquinimod, and Naptumomab.
30GF Score

Get the complete analysis for FRA:BTP

Total Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.41
Price
€0.13
GF Value